Investor · 2 deals
Every published round Canaccord Genuity Australia took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Starpharma | Unnamed stage | 4 Aug 2026 | $32m | Lead | Biotech Dispatch (11 Aug 2026), kalkine.com.au (23 Jul 2026), tipranks.com, Biotech Dispatch (16 Jul 2026), kalkine.com.au (15 Jul 2026) | |
| archTIS Limited | Unnamed stage | 7 Jul 2025 | $7.5m | Lead | ARN (ARNnet), Defence Connect |
Companies Canaccord Genuity Australia has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| archTIS Limited | 7 Jul 2025 | 1 | 1 | |
| Starpharma | Melbourne-based biotech company advancing DEP HER2-Lutetium oncology program | 4 Aug 2026 | 1 | 1 |
Fund closes reported for Canaccord Genuity Australia, as distinct from the investments it has made.
Companies Canaccord Genuity Australia has backed that another company then bought. An exit for the holding, not a deal Canaccord Genuity Australia did.
Stories naming Canaccord Genuity Australia. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Bumi's Australian unit has taken over ASX-listed Loyal Metals for A$79.1 million, with the shares to be delisted; separately, Indonet signed a $530.2 million loan for its subsidiary's data centre build.
A Perth-based maker of military drones has lodged listing paperwork with the corporate regulator ahead of a planned sharemarket float; its current Defence Force munitions contract is worth $24.2 million.
Childcare operator Embark Early Education has locked in a $4 million placement with one US institutional investor, arranged by Canaccord Genuity, to bankroll acquisitions it has yet to identify.
Australian biotech Starpharma has opened a 57-cent shareholder rights issue seeking about $32 million, with Canaccord Genuity underwriting the raise and an oversubscription facility letting holders apply for extra shares.
Also Biotech Dispatch·tipranks.com·kalkine.com.au·Biotech Dispatch
Cyber security firm archTIS has secured $7.5 million via a share placement to fund its US push, partnerships and product development, with Henslow and Canaccord Genuity jointly leading the offer.
Also ARN (ARNnet)
ASX page tables ten companies that have applied to list — mostly mineral explorers, plus defence and AI infrastructure plays — showing proposed codes, pricing, amounts sought, timetables and deal advisers.
ASX-listed medical device maker AirXpanders, based in California, has committed investors for a A$45 million private placement at A$0.92 per CDI, with Canaccord Genuity as sole lead manager, to fund its US commercial launch.
Also GBS Ventures·GBS Ventures
ASX-listed breast reconstruction device maker AirXpanders secured commitments for a 20 million dollar placement at 76 cents per CDI, and appointed Scott Murcray CFO/COO ahead of its planned US launch.